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Abstract                      
Introduction: Serum C-reactive protein (CRP) is believed to be increased in metastatic 
urothelial cancer of the bladder. However, the changes depend on the stage and grade of the 
upper tract urothelial carcinoma (UTUC). This study aimed to compare low-range and high-
range serum CRP and haptoglobin in new cases of UTUC. 
Materials and methods: Blood was collected from newly diagnosed patients with UTUC 
(n=43 patients; 39 male/4 female) and normal individuals (n=26; 24 male and 2 female) with 
no sign of infection or cancer. All the patients showed clinical symptoms of bladder cancer. 
Serum CRP and haptoglobin were estimated based on conventional methods. 
Results: Haematuria and polyuria were common symptoms in 65.12% of the patients suffering 
from UTUC. The serum level of HAPT in control and UTUC patients was 126±13 and 
181±14.5 mg/dl respectively. No significant difference was observed in HAPT level in patients 
and controls. The HAPT was in the high-range level in 27% of controls and 30% of the patients. 
The average serum CRP level in patients and controls was 11.87±3.5 mg/l and 11.45±4.2 mg/l, 
respectively. Serum CRP was above 3.5 mg/l (>3.5 mg/l) in 46% of patients (20/43). The CRP 
level was significantly higher (P=0.023) in patients having CRP above 3.5 mg/l compared to 
respective controls. 
The UTUC patients were separated into two groups based on low-range (<3.5mg/l) and high-
range CRP (>3.5 mg/l).Serum CRP was <3.5 mg/l in 69% of the controls, whereas 31% of 
controls had CRP >3.5 mg/l. However, 46% of UTUC patients had serum CRP > 3.5 mg/l and 
54% of UTUC patients had serum CRP < 3.5 mg/l. 
Conclusion: Although there was no difference in haptoglobin levels in patients and controls, 
but serum CRP was significantly increased in patients and it was associated with clinical 
symptoms of UTUC, suggesting that serum CRP can be considered as a complementary test 
for detection of low-grade UTUC.  
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Introduction 
Urothelial carcinoma is the most common 
malignancy which develops in epithelium 
of bladder, ureter and kidney. Upper 
urinary tract urothelial carcinoma (UTUC) 
and bladder cancer is arising from the 
epithelial lining (i.e., the urothelium) of the 
urinary bladder. It is a disease in which 
abnormal cells multiply without control in 
the bladder (1, 2). 
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Currently, the gold standard for diagnosis 
of bladder cancer is to receive biopsy 
during cystoscopy. In this procedure a 
visual detection by transurethral resection 
of bladder tumor (TURBT) is followed by 
transurethral surgery. Urine cytology is also 
used as an important diagnosis test with 
high specificity but low sensitivity for low-
grade bladder tumors (3). According to Lu 
et al., 2014, only 66.7% of UTUC patients 
show carcinoma cell in urine cytology (4). 
There are also other non-invasive urine 
bound markers available as aids in the 
distinction of bladder cancer, including 
human complement factor H-related 
protein, high-molecular-weight 
carcinoembryonic antigen (CEA), and 
nuclear matrix protein 22 (NMP22) and 
urinary bladder cancer antigen, CYFRA 21-
1 and NMP22 (3, 5, 6). Other non-invasive 
urine based tests include the CertNDx 
Bladder Cancer Assay, which combines 
mutation detection in fibroblast growth 
factor receptor-3 (FGFR3) with protein and 
DNA methylation markers to detect cancers 
across stage and grade, UroVysionTM for 
detection of aneuploidy of chromosome 3,7 
and 17 and loss of 9p21 locus (7-9). 
Interest has been reported in identification 
of reliable biochemical and tumor markers 
for diagnosis of upper tract urothelial 
carcinoma of bladder. In this line very 
recently Lu et al., 2015 (4) used 
immunological and proteomic analysis in 
urine sample to examine the potential value 
of selected markers in UTUC patients. In 
recent years it has been reported that serum 
CRP level is associated with survival of 
patients suffering from various cancers 
including; localized and metastatic renal 
cell carcinoma, upper urinary tract and 
penile cancers (10, 11). 
The progression of UTUC is associated 
with systemic inflammation, but there are 
controversies over the inflammatory 
responses for prediction of cancer 
development. In this line, there are 
controversies over the use of serum C-
reactive protein (CRP) as an acute-phase 
reactant in diagnosis and progression of 
URT. CRP is recognized as an infection and 
inflammatory index; however the 
association of CRP-related responses to 
UTUC malignancy requires further 
investigation. 
The value of serum CRP in diagnosis of 
metastatic urothelial cancer cancers of the 
bladder has been investigated (12). This 
study suggests that the serum CRP value 
prior to regular treatment could be of 
prognostic significance in patients with 
metastatic urothelial cancer of the bladder. 
Likewise, Stein et al. (13), reported that the 
preoperative high levels of serum C-
reactive protein (CRP) is associated with 
locally advanced and metastatic UUT-UC. 
Haptoglobin is also an acute phase protein; 
the main function of this plasma protein is 
to bind to hemoglobin produced as a result 
of hemolysis. There are evidences which 
show that haptoglobin possess antioxidant 
activity and can contribute to the acute 
phase responses. 
The association of serum total haptoglobin 
levels with the development of different 
types of malignancies in humans has been 
investigated. An association between 
alpha-1-antitrypsin and haptoglobin 
phenotype particularly type 2-2 has been 
reported in bladder cancer patients (14).  
According to Kang et al. (15), the 
haptoglobin β-chain is elevated in patients 
suffering from lung cancer, suggesting that 
the haptoglobin β-chain can be used as a 
supportive biomarker for human lung 
cancers. Studies on the haptoglobin 
genotypes (polymorphism) in breast cancer 
patients in Jordan showed that the 
frequency of Hp1 and Hp2 allele is higher 
in non-familial breast cancer compared to 
that in familial breast cancer (15). More 
recently a report from Turkey by Pirinççi et 
al. (16), showed that serum haptoglobin 
levels increases in patients with bladder 
cancer compared to healthy controls. 
Moreover, it was demonstrated that the 
levels of haptoglobin protein increased with 
increasing tumor grades and were 
significantly higher in patients with 


































    
    














 ]  
Original article                                                              J Bas Res Med Sci 2016; 3(4):28-33.  
30 
 
lymphovascular involvement, lymph node 
metastases and increasing tumor burden. It 
has also been demonstrated that elevated 
haptoglobin levels are associated with a 
higher stage, grade, and measure of distant 
metastasis and larger tumor size, suggesting 
that the elevated serum haptoglobin levels 
may provide a useful diagnostic and 
treatment biomarker for patients with 
bladder cancer. 
Despite the studies using either CRP or 
haptoglobin as new biomarkers for 
diagnosis of bladder cancer, there are two 
issues to be addressed in the present case-
control study. Firstly, the implication of 
CRP and/or haptoglobin in early detection 
of low-grade tumors of bladder cancer. This 
can be achieved by measuring these 
parameters in patients prior to systemic 
therapy. Secondly, the usefulness of a 
combined tests (CRP and haptoglobin) for 
early diagnosis of bladder cancer. 
Materials and methods 
Patients and sample collection: This case-
control study was carried out on a group of 
patients with UTUC symptoms and a group 
controls. The patients referred to the 
hospital with urinary complications, such as 
polyuria, dysuria and hematuria. As shown 
in Table 1, the study population consist of 
patients (n=43) and a control group with 
age-and sex match subjects (n=26) who had 
no acute or chronic diseases. 
Blood sample was collected by 
venepuncture from each patient after 
undergoing sonography and cystoscopy. 
After obtaining the demographic 
information of each individual, blood was 
collected; serum was separated and stored 
at freezer for biochemical assays. 
The study protocol conforms to the ethical 
guidelines of the Declaration of Helsinki as 
reflected in the guidelines of the Medical 
Ethics Committee, Ministry of Health of 
Iran. Blood was collected from each subject 
after informed consent was given. 
Measurement of serum CRP: Serum CRP 
was measured by nephelometric method 
using MININEPH™ kit (The Binding Site 
Group Ltd, Birmingham, UK). All the 
assays were carried out in duplicate and the 
results were presented as mean ± SD. 
Estimation of serum haptoglobin: Serum 
Haptoglobin was estimated by 
immunoturbidimetric assay using a 
commercially available kit; Tina-quant 
Haptoglobin ver.2 (Cobas Integra) 
purchased from Roche Diagnostics, 
Mannheim, Germany). In this assay human 
haptoglobin forms a precipitate with a 
specific antiserum which is determined at 
340 nm. 
Results 
In this study levels of CRP and total 
haptoglobin were measured in serum 
samples collected from patients diagnosed 
with bladder cancer (UTUC) based on 
cystoscopy. The patients were new cases 
prior to medical interference. Besides 
serum samples from normal individuals 
were used as control to compare the data. 
As shown in Table 1, most of the cases were 
male and 55.81% of patients were smoking. 
More than 65% of patients (28/43) suffered 
from hematuria.  As shown, all the 43 
patients (100%) underwent 
cystoscopy/sonography as part of diagnosis 
program and proved to be positive for this 
assay. 
 
Table 1. Demographic information of in upper tract 
urothelial carcinoma patients and normal subjects. 
Characteristics  Controls Patients 
Age (year) 44-88 25-86 
Smoking 9(34.61%) 24(55.81%) 





In this study serum CRP levels was 
categorized into two sub-groups (CRP<3.5 
Vs CRP>3.5 mg/l). Based on this, serum 
CRP in approximately 50% of patients was 
above 3.5 mg/l (>3.5 mg/l). The serum CRP 
levels was significantly higher (P<0.05) in 
patients with CRP>3.5 compared to 
respective controls (CRP >3.5 mg/l). 
However CRP levels >3.5 mg/l comprised 
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CRP levels in control samples was <3.5 
mg/l in about 70% (18/26) of control 
samples. 
The samples were divided based on the 
haptoglobin level of less than 200mg/dl and 
those having haptoglobin levels above 200 
mg/dl. In normal samples, 73% (19/26) of 
samples showed haptoglobin between 50 to 
200, whereas 26.9% of the control samples 
showed haptoglobin levels between <50 to 
>200 mg/l. 
In the cancer patients, about 70% of cases 
(30/43) showed low haptoglobin. Whereas, 
30% (13/43) of cases showed high serum 
haptoglobin levels. The minimum level of 
haptoglobin in cancer patients was found to 
be 67.01 mg/dl, whereas in controls 
minimum level was 13.79. Maximum 
serum haptoglobin in the patients and 
controls was 502.17 and 297.58 mg/dl, 
respectively. 
Discussion  
Urinary biomarkers are often measured 
along with urine cytology for diagnosis and 
follow up of UTUC. However the 
sensitivity of these tests is low and may 
even be lower in low-grade tumors. There 
are many types of tumor markers the levels 
of which may be elevated and signify 
metastasis and recurrence of cancer of 
UTUC. 
It has been suggested that serum-based 
tumor markers along with the urine 
cytology which is a specific test for bladder 
cancer can be used for low-grade tumors. 
There are evidences which show that 
inflammatory reactions which appear early 
before tumor formation play important role 
in predisposing epithelial cells to cancerous 
lesions and promotion of cancer. The 
inflammation and infectious conditions can 
trigger immune system and the release of 
immune mediators in circulation. The acute 
phase reactants (APRs) are released in 
response to such conditions. CRP and 
haptoglobin are among the APRs which are 
believed to change as a result of 
inflammatory responses such as cancerous 
lesions. However, the drawback of 
inflammatory mediators as biomarkers is 
their low specificity to a disease such as 
cancer. The use of a marker such as CRP in 
in combination with other markers has been 
suggested for diagnosis of cancers. 
The parameters associated with 
inflammation can be used as 
complementary marker for cancer 
diagnosis particularly at advanced stages of 
tumorigenesis. Changes in serum total 
haptoglobin as well as its chains (alpha and 
beta) have been measured as patients 
suffering from UTUC cancer. The results of 
the present study clearly show that serum 
total haptoglobin is not significantly 
changes in new cases of UTUC subjects. 
These data may suggest that haptoglobin 
level remains within the normal range in 
new diagnosed patients and probably this 
marker is useful for measuring in patient 
with advance cancer and at metastatic stage. 
Haptoglobin changes may also be helpful 
marker if measured in terms of alpha/beta 
chains. Studies revealed that changes in 
expression of haptoglobin chains are 
promising for diagnosis of lung cancer 
(Kang et al., 2001). This finding is further 
confirmed by the report of Park et al.) by 
showing that secretion of alpha and beta 
chains of haptoglobin are significantly 
elevated in patients diagnosed with non-
small cell lung carcinoma (NSCLC). The 
differences in total serum haptoglobin 
between control and bladder patient could 
even be more prominent if measured by 
more sensitive assays such as ELISA. 
According to Pirincci and co-workers), 
ELISA technique can help distinguish 
increased level of serum haptoglobin in 
patients with bladder cancer compared to 
healthy controls. Moreover, using ELISA 
technique it was reported that the levels of 
haptoglobin protein increased with 
increasing tumor gradesand were 
significantly higher in patients with 
metastatic disease and the presence of 
lymphovascular involvement, lymph node 
metastases and increasing tumor burden. 
Serum CRP is often measured for diagnosis 
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inflammation. In diagnostic laboratories, 
the serum level of CRP above 3.5 is 
considered abnormal for cases with 
inflammatory reactions. Currently, CRP is 
not a routine test for diagnosis of bladder 
cancer because there are controversies over 
the range of normal of serum CRP in 
research reports. Saito et al. (20), suggested 
the diagnostic value of serum CRP in terms 
of CRP<5 and CRP>5. However, a 
comparative analysis of these data showed 
that the detection limit of serum CRP>3.5 
is reliable for discrimination between new 
cases of bladder cancer and normal 
samples. 
The use of either of these tests alone or as a 
combined test for prediction of UTUC 
needs assay development considering 
sensitivity and specificity characteristics. It 
appears that these markers may be useful 
for distinguishing normal samples from 
patients at progression or metastasis stages. 
It is worth mentioning that development of 
cancer stages is associated with non-
specific reactions such as inflammation and 
infection. Hence, the elevated factors 
particularly CRP could be assigned to 
tumor-associated responses. This finding 
was further attested by showing that more 
than 45% of UTUC patients had serum CRP 
levels above 3.5 mg/l. In comparison about 
70% of the control individuals had serum 
CRP<3.5 mg/l.  Increased level of serum 
CRP was inconsistent with cystoscopy 
results and symptoms of bladder cancer. 
When comparing the levels of serum total 
haptoglobin and CRP in terms of positive 
was beyond normal range in 26-30% of the 
samples both controls and patients. This 
data suggest that total serum haptoglobin 
has poor diagnostic value for low-grade 
UTUC. Nevertheless, increased serum 
levels of CRP above the normal range in 
approximately 50% of the bladder cancer 
patients may be promising as a biochemical 
diagnostic value in new cases of bladder 
cancer. Moreover, the kinetics of CRP 
release and the analysis of dynamic changes 
in CRP concentrations over time may be 
implicated in prediction of tumor 
aggressiveness and treatment efficacy of 
urological cancers (18) 
In conclusion it appears that although there 
is no strong association between clinical 
signs and symptoms of UTUC and serum 
haptoglobin levels, serum CRP level has 
diagnostic potential as a complementary 
marker for early diagnosis of UTUC.
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